Physician Perspectives on the Food and Drug Administration's Decision to Grant Accelerated Approval to Aducanumab for Alzheimer's Disease
In June 2021, the US Food and Drug Administration (FDA) granted accelerated approval to aducanumab, a monoclonal antibody indicated for the treatment of Alzheimer's disease. The accelerated approval decision was controversial due to concerns about the use of an unvalidated surrogate measure, beta‐amyloid, as the basis for approval and a lack of clinical outcome benefit. Between October 2021 and September 2022, we conducted a survey of a nationally representative group of internists, medical oncologists, and cardiologists to understand perspectives around aducanumab's approval and how this FDA decision may influence trust in other drugs approved through the accelerated approval program. Among 214 physician respondents familiar with the accelerated approval of aducanumab, 184 (86%) would not prescribe or recommend aducanumab. Further, 143 (67%) physicians reported losing trust in other drugs approved through the accelerated approval program due to the FDA's decision with aducanumab. As a growing number of similar novel Alzheimer's disease treatments are on the horizon, the first of which, lecanemab, already has received accelerated approval in January 2023, our survey findings provide insight into the impact of the FDA's regulatory decisions on the perspectives and prescribing behavior of physicians concerning these novel drug treatments..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:114 |
|---|---|
| Enthalten in: |
Clinical Pharmacology & Therapeutics - 114(2023), 3, Seite 614-617 |
| Beteiligte Personen: |
Dhruva, Sanket S. [VerfasserIn] |
|---|
| Anmerkungen: |
© 2023 American Society for Clinical Pharmacology and Therapeutics |
|---|
| Umfang: |
4 |
|---|
| doi: |
10.1002/cpt.2954 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY015401782 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY015401782 | ||
| 003 | DE-627 | ||
| 005 | 20231111143241.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231111s2023 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/cpt.2954 |2 doi | |
| 028 | 5 | 2 | |a 2023-11-11_CPT_2023_114_3.zip.xml |
| 035 | |a (DE-627)WLY015401782 | ||
| 035 | |a (WILEY)CPT2954 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 100 | 1 | |a Dhruva, Sanket S. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Physician Perspectives on the Food and Drug Administration's Decision to Grant Accelerated Approval to Aducanumab for Alzheimer's Disease |
| 264 | 1 | |c 2023 | |
| 300 | |a 4 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 American Society for Clinical Pharmacology and Therapeutics | ||
| 520 | |a In June 2021, the US Food and Drug Administration (FDA) granted accelerated approval to aducanumab, a monoclonal antibody indicated for the treatment of Alzheimer's disease. The accelerated approval decision was controversial due to concerns about the use of an unvalidated surrogate measure, beta‐amyloid, as the basis for approval and a lack of clinical outcome benefit. Between October 2021 and September 2022, we conducted a survey of a nationally representative group of internists, medical oncologists, and cardiologists to understand perspectives around aducanumab's approval and how this FDA decision may influence trust in other drugs approved through the accelerated approval program. Among 214 physician respondents familiar with the accelerated approval of aducanumab, 184 (86%) would not prescribe or recommend aducanumab. Further, 143 (67%) physicians reported losing trust in other drugs approved through the accelerated approval program due to the FDA's decision with aducanumab. As a growing number of similar novel Alzheimer's disease treatments are on the horizon, the first of which, lecanemab, already has received accelerated approval in January 2023, our survey findings provide insight into the impact of the FDA's regulatory decisions on the perspectives and prescribing behavior of physicians concerning these novel drug treatments. | ||
| 700 | 1 | |a Kesselheim, Aaron S. |4 aut | |
| 700 | 1 | |a Woloshin, Steven |4 aut | |
| 700 | 1 | |a Ji, Robin Z. |4 aut | |
| 700 | 1 | |a Lu, Zhigang |4 aut | |
| 700 | 1 | |a Darrow, Jonathan J. |4 aut | |
| 700 | 1 | |a Redberg, Rita F. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical Pharmacology & Therapeutics |g 114(2023), 3, Seite 614-617 |w (DE-627)WLY003995666 |x 15326535 |7 nnns |
| 773 | 1 | 8 | |g volume:114 |g year:2023 |g number:3 |g pages:614-617 |g extent:4 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 114 |j 2023 |e 3 |h 614-617 |g 4 | ||